Innovating Evaluation and Treatment of Intrapartum Fevers: Where Do We Go from Here?

被引:0
|
作者
Wilkie, Gianna L. [1 ,2 ,3 ]
James, Kaitlyn [2 ]
Ona, Samsiya [1 ,2 ]
Easter, Sarah Rae [1 ]
Chou, Joseph [4 ]
Roberts, Drucilla [5 ]
Sahin, Zehra Ordulu [5 ]
Tuomala, Ruth [1 ]
Diouf, Khady [1 ]
Riley, Laura [2 ,6 ]
Prabhu, Malavika [2 ,6 ]
机构
[1] Harvard Med Sch, Dept Obstet & Gynecol, Brigham & Womens Hosp, Boston, MA USA
[2] Harvard Med Sch, Dept Obstet & Gynecol, Massachusetts Gen Hosp, Boston, MA USA
[3] Univ Massachusetts, Dept Obstet & Gynecol, Univ Massachusetts Med Sch, Mem Med Ctr, Worcester, MA USA
[4] Harvard Med Sch, Dept Pediat, Massachusetts Gen Hosp, Boston, MA USA
[5] Harvard Med Sch, Dept Pathol, Massachusetts Gen Hosp, Boston, MA USA
[6] Weill Cornell Med, Dept Obstet & Gynecol, New York, NY USA
关键词
intrapartum fever; early onset sepsis; intraamniotic infection; POLYMERASE-CHAIN-REACTION; EARLY-ONSET SEPSIS; INFLAMMATORY RESPONSE; ANTIBIOTIC USE; MANAGEMENT; RISK; CHORIOAMNIONITIS; INTERLEUKIN-6; BACTEREMIA; NEWBORNS;
D O I
10.1055/s-0041-1727279
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
As intrapartum fevers are not always infectious in origin, determining whether antibiotics are indicated is challenging. We previously sought to create a point-of-care calculator using clinical data available at the time of an intrapartum fever to identify the subset of women who require antibiotic treatment to avoid maternal and neonatal morbidity. Despite the use of a comprehensive dataset from our institutions, we were unable to propose a valid and highly predictive model. In this commentary, we discuss why our model failed, as well as future research directions to identify and treat true intraamniotic infection. Developing a risk-stratification model is paramount to minimizing maternal and neonatal exposure to unnecessary antibiotics while allowing for early identification of women and babies at risk for infectious morbidity.
引用
收藏
页码:250 / 254
页数:5
相关论文
共 50 条
  • [1] Where Do We Go From Here?
    Gilbert, David N.
    JOURNAL OF INFECTIOUS DISEASES, 2015, 212 (11) : 1687 - 1689
  • [2] Hip Ultrasounds: Where do We Go from Here?
    Tamai, Junichi
    JOURNAL OF PEDIATRICS, 2012, 160 (02) : 189 - 190
  • [3] Early intervention in psoriasis: Where do we go from here?
    Felix, Paulo Antonio Oldani
    Sampaio, Ana Luisa
    Silva, Bruno Leonardo
    Viana, Analia Luiza Porto
    FRONTIERS IN MEDICINE, 2022, 9
  • [4] Mass Customization: Where do we go from here?
    Nambiar, Arun N.
    WORLD CONGRESS ON ENGINEERING 2009, VOLS I AND II, 2009, : 687 - 693
  • [5] Orbital retinoblastoma: Where do we go from here?
    Ali, Mohammad Javed
    Reddy, Vijay Anand P.
    Honavar, Santosh G.
    Naik, Milind
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2011, 7 (01) : 11 - 14
  • [6] Audit Committee Research: Where Do We Stand, and Where Do We Go from Here?
    Hermanson, Dana R.
    Hurley, Patrick J.
    Obermire, Kara M.
    AUDITING-A JOURNAL OF PRACTICE & THEORY, 2024, 43 (03): : 165 - 185
  • [7] Where Do We Go from Here? Future Treatment Strategies for Chronic Pain
    Grubb, Tamara
    TOPICS IN COMPANION ANIMAL MEDICINE, 2010, 25 (01) : 59 - 63
  • [8] Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here?
    Lippi, Giuseppe
    Plebani, Mario
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (12) : 2075 - 2080
  • [9] Quality Improvement in Cytology Where Do We Go From Here?
    Renshaw, Andrew A.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2011, 135 (11) : 1387 - 1390
  • [10] Postoperative atrial arrhythmias: Where do we go from here?
    Fernandez, Felix G.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2016, 151 (04) : 990 - 991